Prof Jesus Fernando San-Miguel - University Hospital of Salamanca, Spain
Prof San-Miguel discusses the phase IB, multi-centre, open-label dose-escalation study of oral pPanobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma.